



Corres. and Mail
BOX AF

#15/EF
5/15/01
N.E. 617

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re application of

Takeshi SAKAI et al.

Serial No. 09/269,711

Filed April 5, 1999

APOPTOSIS INDUCING AGENT

Docket No. 00001/F-3511 PT-US

Group Art Unit 1617

Examiner S. Wang

MAY 09 2001

TECH CENTER 1600/2900

RESPONSE UNDER 37. CFR 1.116

EXPEDITED PROCEDURE

EXAMINING GROUP 1617

AMENDMENT AFTER FINAL

Assistant Commissioner for Patents,
Washington, D.C. 20231

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

Sir:

Responsive to the Official Action dated February 7, 2001, please amend the above-identified application as follows:

In the Claims:

Kindly cancel claims 22-39 without prejudice.

Please amend the following claim as indicated.

40. (Amended) A method of inducing apoptosis comprising administering an apoptosis inducing agent which comprises glycerolipid and/or glyceroglycolipid as the effective component(s).

E1
sub
FI